- Conditions
- Bacterial Infections
- Interventions
- RO7223280
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 5
- States / cities
- Sarasota, Florida • Louisville, Kentucky • Royal Oak, Michigan + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 9,360
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2, Pre-diabetes
- Interventions
- G6
- Device
- Lead sponsor
- DexCom, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Lemon Grove, California • Las Vegas, Nevada • New York, New York + 2 more
- Conditions
- Leiomyoma
- Interventions
- BAY1002670, Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 36
- States / cities
- Mesa, Arizona • Tucson, Arizona • San Diego, California + 29 more
- Conditions
- Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
- Interventions
- Ipilimumab, Nivolumab, Cobimetinib, Daratumumab, BMS-986016
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 14
- States / cities
- Gilbert, Arizona • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Alzheimer's Disease
- Interventions
- MK-1942, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Fullerton, California • Sherman Oaks, California + 19 more
- Conditions
- Recurrent or Refractory Pediatric Ependymoma
- Interventions
- erlotinib, etoposide
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Orange, California + 14 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
- Interventions
- Biopsy, Capivasertib, Ceralasertib, Durvalumab, Olaparib, Quality-of-Life Assessment, Selumetinib
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Gordon Mills, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Radial Artery
- Interventions
- Topical Heat
- Procedure
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Endometrial Cancer
- Interventions
- Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 57
- States / cities
- Little Rock, Arkansas • Duarte, California • La Jolla, California + 50 more
- Conditions
- Fibromyalgia
- Interventions
- IMC-1, Placebo BID Tablet
- Drug
- Lead sponsor
- Virios Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Rogers, Arkansas • Oceanside, California + 39 more
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
- Interventions
- parsaclisib, ruxolitinib, placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 36
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Berkeley, California + 29 more
- Conditions
- Hypertension
- Interventions
- clevidipine
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 14
- States / cities
- Montgomery, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Intellectual Disability, Perceptual Disorders, Memory Disorders
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 30 Months to 13 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Oakland, California + 26 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- BG00012, Placebo, Glatiramer Acetate
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more
- Conditions
- Attention Deficit/Hyperactivity Disorder, Emotional Dysfunction, Irritable Mood
- Interventions
- Multinutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants
- Dietary Supplement
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Parkinson's Disease
- Interventions
- Levodopa (delivered intravenously)
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Neoplasms Malignant
- Interventions
- Crizotinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 9
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 4 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Apixaban, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,484 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 221
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 179 more
- Conditions
- Asthma
- Interventions
- BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg, Placebo MDI HFA
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 70
- States / cities
- Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 66 more
- Conditions
- Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
- Interventions
- Carboplatin, Olaparib
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 18
- States / cities
- West Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 15 more
- Conditions
- Bipolar Disorder
- Interventions
- Seroquel®, quetiapine fumarate (atypical antipsychotic), lithium (mood stabilizer), divalproex (mood stabilizer)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 710 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
- Conditions
- Amyloidosis, Hereditary, Transthyretin Amyloidosis
- Interventions
- Patisiran, Vutrisiran
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 15
- States / cities
- La Mesa, California • Aurora, Colorado • Jacksonville, Florida + 12 more
- Conditions
- Meningitis, Meningococcal Infection
- Interventions
- MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus
- Biological
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 55 Days to 89 Days
- Enrollment
- 7,744 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7
- Interventions
- Carboplatin, Cisplatin, Internal Radiation Therapy, Paclitaxel, Quality-of-Life Assessment, Radiation Therapy
- Drug · Radiation · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 813 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2024
- U.S. locations
- 655
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 407 more